Drug price hikes, without justifiable new evidence of benefit — ICER analysis
For patients, policymakers and politicians drug prices in the United States need some lowering, as the sustainability of the US health care system swings from precarious to precipitous. President Trump and every presidential hopeful worth their salt are creating drug price lowering measures to magically cure the ills of the existing system, without curbing innovation or irritating the industry into seeking refuge elsewhere. ICER, the de-facto cost-effectiveness watchdog that is increasingly gaining traction, on Tuesday unveiled an analysis seeking to answer a fundamental question: are these persistent drug price hikes justified?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.